News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
The innovative ‘Street Safe’ Rapid Testing Kit should be provided to all vendors attending the Food Safety and Certification (FoSTaC) trainings to ensure that safe food is used by the street food vendors across the country
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Subscribe To Our Newsletter & Stay Updated
